Article
Single-nucleotide polymorphisms in reductase genes are not associated with response to daunorubicin-based remission induction.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Oct 2013
Lubieniecka Joanna M, Liu Jie, Graham Jinko, Heffner Daniel, Reid Ronald, Hogge Donna, Grigliatti Tom A, Riggs Wayne K
Abstract excerpt
BACKGROUND: To improve the quality of care for patients with acute myeloid leukemia (AML), biomarkers predictive of response to the standard daunorubicin-based induction therapy are needed. Genetic variants affecting daunorubicin metabolism are attractive candidates for such biomarkers. METHODS: We have previously shown that 13 of the naturally occurring nonsynonymous single-nucleotide polymorphisms (SNP) in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.